Search

everythinglearnresearchcommunity

for

Search:↓

The mouse model suggests male pattern baldness may be due to an enzyme increasing DHT and higher androgen receptor levels in hair follicles.

Hair loss in Androgenetic alopecia (AGA) is due to altered cell sensitivity to hormones, not increased hormone levels. Hair growth periods shorten over time, causing hair to become thinner and shorter. This is linked to miscommunication between cell pathways in hair follicles. There's also a change in gene expression related to blood vessels and cell growth in balding hair follicles. The exact molecular causes of AGA are still unclear.

Genetic variants in CYP genes may worsen PCOS symptoms.

The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

Insulin resistance is linked to PCOS and can lead to other health issues, but treatments like metformin can help manage symptoms.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Method accurately measures finasteride in tablets using finasteride-BSA interaction.

New treatments for low male hormones improved sexual function and mood but had unclear risks, especially for older men.

Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.

Lygodii Spora extract may help treat hair loss by blocking a hair loss-related enzyme and promoting hair growth.

Nonclassic congenital adrenal hyperplasia is a genetic disorder causing hormone imbalances, affecting fertility and requiring personalized treatment.

Low prolactin in young women may increase heart and metabolism risks.

The document concludes that treatments for female hair loss and excessive hair growth are temporary and not well-studied.

Testosterone therapy can improve sexual satisfaction and mood in surgically menopausal women when used with estrogen, but its long-term safety and effects on naturally menopausal and premenopausal women are unclear.

Antiandrogens can treat female hormonal conditions, but environmental ones may harm reproductive health.

PCOS is a hormonal disorder causing infertility and menstrual problems, often linked to obesity and can lead to acne, treated with hormonal and insulin-sensitizing medications.

Anabolic steroids can build muscle and strength but have risks and need more research on their clinical benefits and side effects.

Eating less sugar, milk, and saturated fats and more vegetables and fish may help treat and prevent acne.

Current research explores hair growth drugs, while future research aims for personalized treatments.

The document concludes that sex hormones are crucial for mammalian reproduction, health, and behavior, and require more research for therapeutic use.

Spironolactone can reduce hair growth in women with hirsutism.

Targeting glycolysis may help treat PCOS by improving insulin sensitivity and ovarian function.

Hair follicle biology advancements may lead to better hair growth disorder treatments.

Human skin makes sexual hormones that affect hair growth, skin health, and healing; too much can cause acne and hair loss, while treatments can manage these conditions.

Diffuse alopecia in women may be related to androgens and iron deficiency, and basic hormone and nutrient screening is useful.

Growth factors are crucial for hair development and could help treat hair diseases.

Norgestimate is the most effective birth control progestin for reducing an enzyme linked to acne and excessive hair growth in women.

Dermal Papilla cells are a promising tool for evaluating hair growth treatments.